| 1.06 -0.06 (-5.36%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.32 |
1-year : | 1.51 |
| Resists | First : | 1.13 |
Second : | 1.29 |
| Pivot price | 1.12 |
|||
| Supports | First : | 0.86 |
Second : | 0.72 |
| MAs | MA(5) : | 1.12 |
MA(20) : | 1.15 |
| MA(100) : | 1.72 |
MA(250) : | 2.71 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 46 |
D(3) : | 54.2 |
| RSI | RSI(14): 44.7 |
|||
| 52-week | High : | 4.09 | Low : | 0.68 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ OVID ] has closed above bottom band by 23.0%. Bollinger Bands are 71.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.15 - 1.16 | 1.16 - 1.17 |
| Low: | 1.01 - 1.02 | 1.02 - 1.03 |
| Close: | 1.05 - 1.06 | 1.06 - 1.07 |
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Thu, 12 Sep 2024
Ovid Therapeutics appoints new president and COO - Investing.com
Wed, 11 Sep 2024
Ovid Therapeutics Elevates Meg Alexander to President and COO - TipRanks
Wed, 11 Sep 2024
Meg Alexander Appointed COO of Ovid Therapeutics - citybiz
Wed, 11 Sep 2024
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth - StockTitan
Wed, 04 Sep 2024
Ovid Therapeutics to Present at Upcoming September Investor Conferences - StockTitan
Wed, 04 Sep 2024
Ovid Therapeutics to Present at Upcoming September Investor Conferences - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 71 (M) |
| Held by Insiders | 4.646e+007 (%) |
| Held by Institutions | 15.9 (%) |
| Shares Short | 1,070 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.578e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -11 % |
| Return on Assets (ttm) | 75.1 % |
| Return on Equity (ttm) | -32.7 % |
| Qtrly Rev. Growth | 567700 % |
| Gross Profit (p.s.) | 329.73 |
| Sales Per Share | -78.45 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -53 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.32 |
| Dividend | 0 |
| Forward Dividend | 721300 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|